Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
WuXi AppTec H | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$180.36B | 22.3x | -1.47 | HK$62.45 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3% Upside | Upgrade to Pro+ | |
WuXi Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$98.75B | 22.9x | -0.93 | HK$24 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.2% Downside | Upgrade to Pro+ | |
Akeso | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$63.37B | -74.9x | 0.6 | HK$70.85 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.3% Upside | Upgrade to Pro+ | |
Sichuan Kelun Biotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$55.64B | -188x | -4.13 | HK$239.60 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.5% Downside | Upgrade to Pro+ | |
Tigermed | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$53B | -0.82 | HK$39.20 | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Pharmaron Beijing Co Ltd | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$51.61B | 25.5x | 1.13 | HK$16.02 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18% Upside | Upgrade to Pro+ | |
Genscript Biotech Corp | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$28.09B | -20x | -4.46 | HK$13.12 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Innocare | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$18.75B | -28.9x | -1.37 | HK$8.96 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -8.5% Downside | Upgrade to Pro+ | |
Joinn Laboratories China Co | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$17.33B | -22,150x | HK$15.82 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -38.6% Downside | Upgrade to Pro+ | ||
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$15.67B | -3.1x | -1.49 | HK$146.50 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.8% Upside | Upgrade to Pro+ | |
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$15.09B | -5.8x | -3.98 | HK$16.48 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.4% Upside | Upgrade to Pro+ | |
Lepu Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.78B | -49.2x | -0.88 | HK$3.36 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lepu Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.78B | -49.2x | -0.88 | HK$3.37 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.71B | -25.5x | -0.55 | HK$37 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.5% Upside | Upgrade to Pro+ | |
TYK Medicines | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$12.02B | -11x | HK$30.90 | -4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Keymed Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$9.69B | -13.4x | 0.07 | HK$35.05 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CARsgen Therapeutics Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$7.82B | -8.1x | -0.48 | HK$14.28 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -28.8% Downside | Upgrade to Pro+ | |
Alphamab | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.99B | -13.9x | -64.87 | HK$5.07 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -33.6% Downside | Upgrade to Pro+ | |
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.94B | 171.3x | 1.47 | HK$8.04 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.7% Upside | Upgrade to Pro+ | |
Biocytogen Pharmaceuticals Beijing | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.90B | -11.4x | -0.34 | HK$12.98 | 5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.2% Upside | Upgrade to Pro+ | |
CStone | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$4.29B | -21.4x | -0.35 | HK$3.50 | 4.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.2% Upside | Upgrade to Pro+ | |
Jiangsu Recbio Technology | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$3.92B | -6.8x | -0.47 | HK$8.17 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Immunotech | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.43B | -4.6x | 1.9 | HK$4.78 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hua Medicine | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.36B | -8.5x | 0.21 | HK$2.40 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.8% Upside | Upgrade to Pro+ | |
Jacobio Pharmaceuticals Group | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.28B | -2.7x | -0.39 | HK$2.86 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -35.5% Downside | Upgrade to Pro+ | |
Antengene | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.24B | -0.8x | -0.17 | HK$3.26 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -61% Downside | Upgrade to Pro+ | |
Frontage Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.10B | 40.4x | -0.68 | HK$1.04 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -4.4% Downside | Upgrade to Pro+ | |
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$2.02B | -5.9x | 1.64 | HK$0.65 | 32.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ImmuneOnco Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.98B | -5.4x | -8.96 | HK$4.89 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qyuns Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.93B | -11x | HK$7.12 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Brii Biosciences | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.71B | -2.4x | -0.28 | HK$2.72 | 15.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -63% Downside | Upgrade to Pro+ | |
Tot Biopharm Intl | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1.62B | 142.2x | 1.38 | HK$2.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.6% Upside | Upgrade to Pro+ | |
Genor Biopharma Holdings | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$1B | -1.5x | -0.15 | HK$1.94 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Wuhan YZY Biopharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$862.63M | -5.8x | -0.59 | HK$4.45 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Jw Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$801.11M | -0.9x | -0.06 | HK$2.02 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.6% Upside | Upgrade to Pro+ | |
Sunho Biologics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$605.68M | -3.5x | HK$4.09 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
HighTide Therapeutics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$550.80M | -0.7x | -0.09 | HK$1.09 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kintor Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$497.91M | -0.4x | 0.01 | HK$1.20 | 4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Clover Biopharmaceuticals | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$421.55M | -0.4x | 0.02 | HK$0.33 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sirnaomics | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$318.25M | -0.4x | -0.17 | HK$3.12 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Health Inc | Hong Kong | Healthcare | Biotechnology & Medical Research | HK$168.21M | -2.8x | 0.01 | HK$0.17 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |